https://iro.uiowa.edu/esploro/outputs/letter/Pegcetacoplan-in-C3-Glomerulopathy-and-Immune-Complex/9985147183002771
Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN - University of Iowa
To the Editor: The results of the VALIANT trial reported by Fakhouri et al. (Dec. 4 issue)1 provide compelling evidence that proximal C3 inhibition with...
university of iowaimmune complexpegcetacoplanglomerulopathympgn
https://empaveli.com/
EMPAVELI (pegcetacoplan) | Patient Informational Website
Sep 4, 2026 - Explore EMPAVELI as a possible treatment option for adults with PNH and for adults and adolescents (12 years of age and older) with C3G or primary IC-MPGN.
empavelipegcetacoplanpatientinformational
https://empavelihcp.com/c3g/dosing-administration/
Dosing | EMPAVELI® (pegcetacoplan) for C3G & Primary IC-MPGN
Aug 13, 2026 - Learn about self-administration guidance, dosing information, and how to start your patients on EMPAVELI® (pegcetacoplan).
dosingpegcetacoplanprimarympgn
https://consultqd.clevelandclinic.org/pegcetacoplan-offers-new-hope-for-treating-dry-macular-degeneration
Pegcetacoplan Offers New Hope for Treating Dry Macular Degeneration
Intravitreal injections of pegcetacoplan can significantly slow the progression of dry macular degeneration, a study shows. There currently is no treatment for...
dry macular degenerationnew hopepegcetacoplanofferstreating